Scholarlink

<p>To understand the research progress and trends of nanoagents for breast cancer treatment, this paper presents a bibliometric analysis using data collected from the Web of Science Core Collection database for the period from January 1, 2002, to December 31, 2023. The analysis was conducted using VOSviewer and CiteSpace, focusing on the number of annual publications, co-authors, co-occurrences of co-citations, countries, institutions, authors, documents, and keywords. A total of 2996 papers were included. The results showed that the number of publications on breast cancer nanoagents began to grow rapidly after 2015, with the total citation frequency continuing to increase, indicating that the scope and depth of related research results are gradually expanding and deepening. China published the most papers (41.36%, 1239 papers), followed by the USA (26.50%, 793 papers) and India (10.50%, 314 papers). However, the total citation frequency of the USA is the highest, indicating that the influence of Chinese scholars’ papers in this field still needs improvement. The Chinese Academy of Sciences has the largest number of papers among the issuing organizations. Research hotspots in breast cancer nanoformulations focus on nanoparticle drug delivery systems and in vivo and in vitro treatments of breast cancer. Significant increases in searches were observed for keywords such as solid lipid nanoparticles, albumin-bound paclitaxel, iron oxide nanoparticles as drug carriers, in vivo targeted drug delivery systems of anticancer drugs, and combining photodynamic therapy to improve the tumor microenvironment. This indicates a promising research field. In the future, more attention should be paid to research directions such as the application of nanoscale device technology in anti-breast cancer therapy, reproducible and scalable nanoparticle synthesis, screening and evaluation, and the incorporation of new molecular entities and novel therapeutic agents to promote clinical integration and development.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Research progress and hotspots of nanoagents for breast cancer based on bibliometric analysis

  • 期刊论文

  • 发表日期：

    2025年12月3日

查看全文
  • Weiju Liao,
  • Runfang Deng,
  • Lingling Wu,
  • Dongyi Huang,
  • Tingting Huang,
  • Xingzhen Huang

摘要

To understand the research progress and trends of nanoagents for breast cancer treatment, this paper presents a bibliometric analysis using data collected from the Web of Science Core Collection database for the period from January 1, 2002, to December 31, 2023. The analysis was conducted using VOSviewer and CiteSpace, focusing on the number of annual publications, co-authors, co-occurrences of co-citations, countries, institutions, authors, documents, and keywords. A total of 2996 papers were included. The results showed that the number of publications on breast cancer nanoagents began to grow rapidly after 2015, with the total citation frequency continuing to increase, indicating that the scope and depth of related research results are gradually expanding and deepening. China published the most papers (41.36%, 1239 papers), followed by the USA (26.50%, 793 papers) and India (10.50%, 314 papers). However, the total citation frequency of the USA is the highest, indicating that the influence of Chinese scholars’ papers in this field still needs improvement. The Chinese Academy of Sciences has the largest number of papers among the issuing organizations. Research hotspots in breast cancer nanoformulations focus on nanoparticle drug delivery systems and in vivo and in vitro treatments of breast cancer. Significant increases in searches were observed for keywords such as solid lipid nanoparticles, albumin-bound paclitaxel, iron oxide nanoparticles as drug carriers, in vivo targeted drug delivery systems of anticancer drugs, and combining photodynamic therapy to improve the tumor microenvironment. This indicates a promising research field. In the future, more attention should be paid to research directions such as the application of nanoscale device technology in anti-breast cancer therapy, reproducible and scalable nanoparticle synthesis, screening and evaluation, and the incorporation of new molecular entities and novel therapeutic agents to promote clinical integration and development.

Graphical Abstract